Recent Advances in Understanding the Pathogenesis of Atherosclerosis in CKD Patients

A need exists for developing new therapies to improve cardiovascular outcomes in end-stage kidney disease. Three new areas that address novel pathophysiological mechanisms and/or therapeutic approaches toward cardiovascular events in chronic kidney disease patients include the use of an anti-inflammatory agent, the role of catalytic iron, and protein carbamylation. In preliminary studies, hydroxychloroquine, which has multiple anti-inflammatory properties, preserved vascular compliance for the aorta and major vessels, as well as reduced the extent of severity of atherosclerosis in ApoE−/− mice.
Source: Journal of Renal Nutrition - Category: Urology & Nephrology Authors: Tags: Icurt Proceedings Source Type: research

Related Links:

Publication date: 12 November 2019Source: Cell Reports, Volume 29, Issue 7Author(s): Lucie Yammine, Aniela Zablocki, William Baron, Fabiola Terzi, Morgan GallazziniSummaryEpidermal growth factor receptor (EGFR) activation and lipocalin-2 (Lcn2) expression are frequently observed in the same pathological contexts, such as cancers or chronic kidney disease (CKD). However, the significance of this association is unknown. Here, we describe the role of Lcn2 in regulating EGFR trafficking. We show that Lcn2 increases EGFR cell surface abundance and is required for transforming growth factor α (TGF-α)-induced EGFR rec...
Source: Cell Reports - Category: Cytology Source Type: research
Conclusions: There was no statistical significant association between any of the studied heavy metals and CKD, although there was a significant burden of heavy metals in the studied subjects.
Source: Indian Journal of Nephrology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionsIn patients with CKD referred for right heart catheterization, PH is common and associated with poor survival. Combined pre- and postcapillary PH was common and portended the worst survival for patients with CKD
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Vitamin D and fish oil fall flat again in type 2 diabetes and chronic kidney disease. But this is not a bad thing, says Dr F. Perry Wilson.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Nephrology Commentary Source Type: news
WEDNESDAY, Nov. 13, 2019 -- The incidence of encephalopathy is increased with prescription of higher versus lower doses of baclofen among older patients with chronic kidney disease (CKD), according to a study published online Nov. 9 in the Journal...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 11 November 2019Source: Chemico-Biological InteractionsAuthor(s): Nehal M. Elsherbiny, Eman Said, Hoda Atef, Sawsan A. ZaitoneAbstractType 2 diabetes mellitus (T2DM) is a disease with a drastically growing worldwide prevalence. It is usually associated with numerous complications of which; diabetic nephropathy (DN); is a main complication of microvasculature and more seriously, a common cause of end-stage renal disease (ESRD). Unfortunately, both the lack of a definitive remedy alongside the economic and the social burden on DN patients enforces considerable impetus for developing alterna...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Dysfunctional high-density lipoprotein (d-HDL) in chronic kidney disease is known to have a change in composition towards an endothelial-damaging phenotype, amongst others, via the accumulation of symmetric dimethylarginine. The endothelial glycocalyx, a carbohydrate-rich layer lining the endothelial luminal surface, is a first line defense against vascular diseases including atherosclerosis. Here we conducted a translational, cross-sectional study to determine the role of symmetric dimethylarginine in d-HDL as a mediator of glycocalyx damage.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Basic Research Source Type: research
AbstractLow-molecular-weight heparins (LMWHs) are the mainstay of the prophylaxis and treatment of venous thromboembolism (VTE). Due to their renal elimination, the risk of accumulation with the related bleeding risk may represent a limitation for the use of LMWHs in patients with chronic kidney disease (CKD) as the risk of major bleeding is increased in patients with creatinine clearance (CrCl)
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
Obesity is an independent risk factor for renal functional decline in people with chronic kidney disease and is highly prevalent amongst people with the leading cause of chronic kidney disease, diabetic kidney disease [1]. Intentional weight loss strategies hold promise as a means of arresting progressive renal functional decline in diabetic kidney disease [2]. Optimisation of renal outcomes after metabolic surgery centres on blood pressure and glycaemic control as well as addressing proteinuria.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Source Type: research
Chronic kidney disease (CKD) affects more than 10% of the population worldwide and burdens citizens with heavy medical expenses in many countries. Because a vital erythroid growth factor, erythropoietin (EPO), is secreted from renal interstitial fibroblasts [renal EPO-producing (REP) cells], anemia arises as a major complication of CKD. We determined that hypoxia-inducible factor 2α (HIF2α), which is inactivated by HIF-prolyl hydroxylase domain-containing proteins (PHDs) in an oxygen-dependent manner, tightly regulates EPO production in REP cells at the gene transcription level to maintain oxygen homeostasis. H...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Heart | Hydroxychloroquine | Nutrition | Study | Urology & Nephrology